RxDoctor Payments Data

Raymond Wong, DO

Internal Medicine · Elmira, NYNPI 1275945990

Payments from drug & device makers

$1,082in general payments, 2019–2025

Across 61 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$237
  • Amgen$115
  • Pfizer$107
  • Kowa Pharmaceuticals America, Inc.$89
  • AbbVie$76
  • Johnson & Johnson$73
  • plus $385 from 10 others

What the payments were for

  • Food & beverage$1,07699%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,082 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$88,907
Medicare patients
126
Services billed
1,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$55,035
OzempicSemaglutide51$51,650
EliquisApixaban48$40,426
JanuviaSitagliptin Phosphate30$27,491
TrulicityDulaglutide27$26,293
FarxigaDapagliflozin Propanediol32$20,284
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,415
XareltoRivaroxaban12$13,879
Ezetimibe39$3,339
Albuterol Sulfate HfaAlbuterol Sulfate80$2,474
Gabapentin128$1,904
Rosuvastatin Calcium95$1,638
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc15$1,478
Tamsulosin Hcl80$1,463
Atorvastatin Calcium123$1,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$34$55,03549 claims
Novo NordiskOzempic$29$51,65051 claims
PfizerEliquis$107$40,42648 claims
MerckJanuvia$32$27,49130 claims
Lilly USA, LLCTrulicity$66$26,29327 claims
AstraZenecaFarxiga$237$20,28432 claims
GSKTrelegy Ellipta$25$17,41518 claims
Johnson & JohnsonXarelto$73$13,87912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →